141 related articles for article (PubMed ID: 29478263)
1. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States.
Li J; Zhang T; Gordon SC; Rupp LB; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
J Viral Hepat; 2018 Aug; 25(8):952-958. PubMed ID: 29478263
[TBL] [Abstract][Full Text] [Related]
2. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
Aliment Pharmacol Ther; 2019 Mar; 49(5):599-608. PubMed ID: 30650468
[TBL] [Abstract][Full Text] [Related]
6. Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome.
Pandya P; Pant C; Taylor R; Oni O
J Investig Med; 2017 Apr; 65(4):765-771. PubMed ID: 28232517
[TBL] [Abstract][Full Text] [Related]
7. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
Lu M; Li J; Rupp LB; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Zhou Y; Boscarino JA; Schmidt MA; Lamerato LE; Trinacty C; Trudeau S; Gordon SC;
J Viral Hepat; 2016 Sep; 23(9):718-29. PubMed ID: 27028626
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
10. Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.
Lu M; Li J; Zhang T; Rupp LB; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Xu F; Boscarino JA; Schmidt MA; Vijayadeva V; Gordon SC;
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1044-1055.e3. PubMed ID: 26804385
[TBL] [Abstract][Full Text] [Related]
11. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
13. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
[TBL] [Abstract][Full Text] [Related]
14. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.
Moon AM; Green PK; Rockey DC; Berry K; Ioannou GN
Aliment Pharmacol Ther; 2020 Feb; 51(3):364-373. PubMed ID: 31773763
[TBL] [Abstract][Full Text] [Related]
16. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
[TBL] [Abstract][Full Text] [Related]
17. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
18. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Hirakawa M; Ikeda K; Kumada H
Hepatology; 2009 Mar; 49(3):739-44. PubMed ID: 19127513
[TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
20. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]